Source comparison
4. DAC vs No DAC: Why Safety Profiles May Differ
The biggest safety distinction within the CJC-1295 category is duration of exposure. CJC-1295 with DAC includes a drug-affinity-complex modification that binds albumin and extends activity. In healthy adults, DAC-modified CJC-1295 produced dose-dependent GH in
This comparison does not assign a generated winner or score.
- The biggest safety distinction within the CJC-1295 category is duration of exposure.
- CJC-1295 with DAC includes a drug-affinity-complex modification that binds albumin and extends activity. In healthy adults, DAC-modified CJC-1295 produced dose-dependent GH increases for six days or more and IGF-1 increases for nine to eleven days after a single injection; after multiple doses, mean IGF-1 remained above baseline for up to 28 days.
- CJC-1295 No DAC, commonly called Modified GRF (1-29), lacks the albumin-binding extension and is shorter acting. It is more relevant to transient GHRH receptor activation rather than prolonged GH/IGF-1 exposure.
- Feature
- CJC-1295 with DAC
- CJC-1295 No DAC / Modified GRF (1-29)
- DAC extension
- Yes
- No
- Albumin binding
- No DAC-mediated binding
- Duration
- Long-acting
- Shorter-acting
- Main safety issue
- Limited direct human safety data
- Strongest evidence
- Human clinical studies
- GHRH analog / Modified GRF / sermorelin literature
- FDA has flagged CJC-1295 category safety concerns
- Still affected by naming and sourcing ambiguity
- Why it matters: It is not scientifically clean to copy the safety profile of DAC-modified CJC-1295 onto No DAC / Modified GRF (1-29). They share the same core receptor pathway, but their exposure profiles are different.